Showing posts with label IBD. Show all posts
Showing posts with label IBD. Show all posts

Thursday, January 31, 2019

Four trials published in 2018 that may shape neurology practice




  • A new treatment option for brain metastases: The usual survival period after brain metastases is 2-4 months. Brain metastasis generally means palliative care. In a study published online August 2018 in the New England Journal of Medicine (N Engl J Med. 2018;379:722-730), nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had asymptomatic untreated brain metastases. Benefit in intracranial growth of metastases was seen in 57% of patients, 64% of patients did not show any progression of the disease, and the 6-month survival was 80%.

  • Gut linked to pathophysiology of Parkinson’s disease: JAMA Neurology provided indirect evidence for role of systemic inflammation in the pathogenesis of Parkinson disease and inflammatory bowel disease in a retrospective cohort study of 144,018 patients with IBD (JAMA Neurol. 2018;75:939-46). Patients with IBD had a 28% higher incidence of Parkinson’s disease. A marked reduction in the incidence of Parkinson’s disease was observed when IBD patients were treated with anti–tumor necrosis factor therapy.

  • No beneficial effect of aspirin for prevention of adverse CV events in moderate risk patients: The multicenter ARRIVE study compared the use of aspirin with placebo in more than 12,000 patients with moderate risk of heart disease (10-year risk of coronary heart disease 10-20%) (Lancet. 2018;392:1036-46). No beneficial effects with regard to the primary efficacy endpoint (composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina, stroke, or transient ischemic attack) were seen with aspirin after a follow-up period of 60 months.  Gastrointestinal bleeding events (mild) occurred more often with aspirin. Use of aspirin in moderate-risk patients needs to be individualized.

  • Major bleeding risks offset primary prevention benefits of aspirin use in patients with diabetes: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease (19% risk reduction) in the ASCENT trial (N Engl J Med. 2018;379:1529-39). Major bleeding events occurred in 314 participants in the aspirin group vs 245 in the placebo group indicating a 30% increase in the risk of major bleeding. So, the absolute benefits were largely counterbalanced by the bleeding hazard. 

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA

Wednesday, December 19, 2018

IBD may be an independent risk factor for heart disease


Patients with inflammatory bowel disease (IBD) are at a significantly higher risk of myocardial infarction (MI), says a study reported in the journal Inflammatory Bowel Diseases, online November 30, 2018. The relative risk of MI was highest in younger patients and decreased with age.

The researchers examined a nationwide database of medical records for more than 29 million people, of which, 131,680 had ulcerative colitis and 158,750 had Crohn's disease. Over the 5-year study period, patients with IBD had 25% greater probability to suffer a heart attack when compared to those without IBD.

Around 8.8% of patients with Crohn's disease suffered a heart attack during the study period. Likewise, 6.7% of patients with ulcerative colitis had a heart attack. In contrast, the prevalence of MI was just 3.3% in persons without IBD.

The risk was highest during active flares or persistent disease, while a reduction in risk was observed, when the disease was in remission. The odds of MI in IBD patients overall were highest in younger patients and decreased with age (age 30–34 years: OR 12.05 [11.16–13.01], age 65+ years: OR 2.08 [2.04–2.11]), which means that IBD patients aged 30 to 34 years were 12 times more likely to have a heart attack than their counterparts; IBD patients aged 65 years only about twice as likely to have MI as persons without IBD.

The inflammatory process in IBD has been implicated as the factor that predisposes these patients to develop a heart attack. The chronic inflammation promotes clot formation, which may block the coronary arteries and incite an acute heart event.

These findings suggest that IBD may be an independent risk factor for heart disease and emphasize the need for aggressive risk factor reduction in these patients.

IBD patients should be closely watched for risk factors for heart disease such as hypertension, diabetes, smoking, obesity, high cholesterol.

Since the risk was found to be low when the disease was in remission, keeping IBD under control as well as modifying risk factors can reduce the risk of heart attack in these patients.

(Source: Panhwar MS, et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based national study. Inflamm Bowel Dis. 2018 Nov 30. doi: 10.1093/ibd/izy354)


Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA